- Home
- ASAN vs AKRO Comparison
ASAN vs AKRO Comparison
Compare ASAN & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASAN
- AKRO
- Stock Information
- Founded
- ASAN 2008
- AKRO 2017
- Country
- ASAN United States
- AKRO United States
- Employees
- ASAN N/A
- AKRO N/A
- Industry
- ASAN Retail: Computer Software & Peripheral Equipment
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- ASAN Technology
- AKRO Health Care
- Exchange
- ASAN Nasdaq
- AKRO Nasdaq
- Market Cap
- ASAN 4.3B
- AKRO 3.9B
- IPO Year
- ASAN 2020
- AKRO 2019
- Fundamental
- Price
- ASAN $17.90
- AKRO $49.65
- Analyst Decision
- ASAN Hold
- AKRO Strong Buy
- Analyst Count
- ASAN 18
- AKRO 8
- Target Price
- ASAN $16.06
- AKRO $82.50
- AVG Volume (30 Days)
- ASAN 2.2M
- AKRO 1.9M
- Earning Date
- ASAN 06-03-2025
- AKRO 05-12-2025
- Dividend Yield
- ASAN N/A
- AKRO N/A
- EPS Growth
- ASAN N/A
- AKRO N/A
- EPS
- ASAN N/A
- AKRO N/A
- Revenue
- ASAN $723,876,000.00
- AKRO N/A
- Revenue This Year
- ASAN $10.21
- AKRO N/A
- Revenue Next Year
- ASAN $9.67
- AKRO N/A
- P/E Ratio
- ASAN N/A
- AKRO N/A
- Revenue Growth
- ASAN 10.94
- AKRO N/A
- 52 Week Low
- ASAN $11.05
- AKRO $17.86
- 52 Week High
- ASAN $27.77
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- ASAN 57.31
- AKRO 63.34
- Support Level
- ASAN $16.85
- AKRO $44.94
- Resistance Level
- ASAN $18.72
- AKRO $49.29
- Average True Range (ATR)
- ASAN 0.64
- AKRO 3.33
- MACD
- ASAN -0.02
- AKRO 0.67
- Stochastic Oscillator
- ASAN 56.15
- AKRO 86.02
About ASAN Asana Inc.
Asana is a provider of collaborative work management software delivered via a cloud-based SaaS model. The firm's solution offers scalable, dynamic tools to improve the efficiency of project and process management across countless use cases, including marketing programs, managing IT approvals, and performance management. Asana's offering supports workflow management across teams, provides real time visibility into projects, and reporting and automation capabilities. The firm generates revenue via software subscriptions on a per seat basis.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.